Clinical Trials Logo

Newly Diagnosed clinical trials

View clinical trials related to Newly Diagnosed.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04554485 Completed - Newly Diagnosed Clinical Trials

Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)

Blina-CELL
Start date: May 9, 2019
Phase: Phase 2
Study type: Interventional

This is a phase II interventional trial to evaluate the efficacy of blinatumomab followed by high-dose chemotherapy in the first-line treatment for Ph-negative acute lymphoblastic leukemia (ALL) in adults. The aim is to increase the number of complete molecular responses after first two cycles of therapy. Early molecular response is considered to be the most powerful prognostic factor in ALL. Thus, a higher proportion of early molecular responses should translate into improved survival and fewer indications for allogeneic stem cell transplants

NCT ID: NCT01147627 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients

Start date: August 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate and evaluate the effects of different interventions (1. exenatide, 2. insulin, 3. thiazolidinedione) on glycemic control and β-cell function in newly diagnosed drug-naïve type 2 diabetic patients.

NCT ID: NCT00632255 Completed - Clinical trials for Chronic Myeloid Leukemia

Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment

Start date: January 2008
Phase:
Study type: Observational

Imatinib has revolutionised the treatment of chronic myeloid leukaemia (CML). The first clinical trials were conducted in 1998 in patients with advanced disease, and by 2002 imatinib was established as the standard therapy for all patients including those recently diagnosed. In spite of overwhelming evidence about its efficacy we still need to gain more knowledge about issues related to long term treatment with imatinib such as why some patients respond better than others, the development of side effects and the quality of life.